ESKALITH (lithium carbonate) by Enthera Pharmaceuticals is 12. First approved in 1979.
Drug data last refreshed 15m ago · AI intelligence enriched 1w ago
ESKALITH (lithium carbonate) is an oral small-molecule mood stabilizer used primarily in bipolar disorder management. The mechanism of action remains unknown despite decades of clinical use. It is absorbed rapidly in the upper GI tract, distributes throughout total body water, and is excreted unchanged via the kidneys with an 18-36 hour half-life.
Product approaching loss of exclusivity signals defensive commercial strategy; expect focus on retention, adherence programs, and generic transition planning rather than growth initiatives.
12.1 Mechanism of Action The mechanism of action of lithium as a mood stabilizing agent is unknown. 12.3 Pharmacokinetics Absorption: After oral administration, lithium is reported to be completely absorbed in the upper gastrointestinal tract. Peak serum concentrations (T max ) occur 0.25 to 3…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects
Worked on ESKALITH at Enthera Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ESKALITH at LOE Approaching stage positions professionals for defensive commercial and market access expertise in generic transition. Roles emphasize retention strategy, payer negotiation, and operational efficiency rather than growth marketing, making this attractive for those specializing in late-stage lifecycle management.